| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Addex Therapeutics Ltd$6.45
+0.25 (+4.03%)
D 34Pipeline Score Overvalued Pharma · Clinical
Market Cap
6.89 M
EPS
-9.10
P/E Ratio
-0.7 $
Value Trade
6.33 K
0.29 %
Week
-2.43 %
1 Month
-7.07 %
3 Month
-13.54 %
6 Month
-96.52 %
5 Year
-97.64 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
21.35 K
52 Week Range
5.41 - 12.05
% held by Insiders
0.03 %
% held by Institutions
0.05 %
Enterprise Value
4.86 M
Total Shares
982.73 K
Short %
0.51 %
Float Shares
982.44 K
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D34
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 45%
Micro Cap (rank 499 of 905)
Percentile RankAddex Therapeutics Ltd faces pipeline headwinds (34/100), with $983M risk-adjusted pipeline value, led by ADX10059 in Gastroesophageal Reflux (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX10059 Small molecule | Gastroesophageal Reflux | Phase 2 | NCT00820079 | 16% | $679M | COMPLETED | 418 | - | - | — | - | Dec 24, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 | |||
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 | |||
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADXN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ADXN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Addex Therapeutics Ltd (ADXN) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How ADXN ranks across every disease it competes in No competitive intelligence available for ADXN.